NASDAQ
239.77USD
-1.78 (-0.74%)
We have scored 28 news catalysts on Jazz Pharmaceuticals plc (JAZZ) over the past 12 months. The biggest single-day move next to one of them came Aug 26, 2026, when JAZZ closed −4.2%: “Jazz Pharmaceuticals plc (JAZZ) Discusses FDA Approval and Commercial Launch of ZIIHERA for First-Line HER2-Positive GEA Transcript”. Coverage across the window leans positive (average ticker sentiment +0.39). Most of the impact sits in sector healthcare and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
15.4B
P/E
—
EPS
—
Beta
0.32
52W range
156.95-266.38
Day range
238.93–244.61
Open
243.30
Prev close
241.55
Volume
490.2K
Avg volume
848.6K
Dividend
0.00
IPO
2007-06-01
Analysts publish price targets on JAZZ, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
29 analyst price targets from $253 to $337
as of 2026-09-24
The market is 17% below the median target — more cautious than the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Jazz Pharmaceuticals plc — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for JAZZ: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
At $240, the stock sits at the very bottom of the 29 published models, rejecting the entire bull case and leaning heavily bearish against the analysts' median target of $285.
What the disagreement turns on
The central question is whether Ziihera and the rare disease pipeline can generate the multi-billion dollar revenues the bull models assume, or whether the price is correct to treat them as marginal additions; unit volume data for Ziihera's launch can begin to settle this, but pipeline probability remains unmeasurable here.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
Computed at $236 on 2026-09-24 — 54 days ago.